Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis

Liu, Yaosheng; Qing, Haifeng; Su, Xiuyun; Wang, Cheng; Zhou, Li; Liu, Shubin

doi:10.12659/msm.894357

Cited by 27 publications

(30 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that CD44 genetic polymorphisms are closely associated with NSCLC genesis, bone metastasis, and TNM stage [13,14]. Independently of the TNM stage, CD44 genetic polymorphisms are predictive of a poor prognosis in postoperative NSCLC patients, especially in those with lung adenocarcinoma [15].…”

Section: Discussionmentioning

confidence: 97%

Expression of Novel CD44st and MMP2 in NSCLC Tissues and Their Clinical Significance

Zhang

Hai

et al. 2017

Oncol Res Treat

View full text Add to dashboard Cite

Background: Abnormal expression of some CD44 molecules in tumor tissues can induce the degradation of the extracellular matrix, and is closely associated with axillary lymph node metastasis, angiogenesis, cancer progression, and drug resistance. Patients and Methods: We measured and confirmed the expression of CD44st and MMP2 mRNAs and proteins in the cancer tissues and adjacent normal tissues of postoperative non-small cell lung cancer (NSCLC) patients with either adenocarcinoma (n = 72) or squamous cell carcinoma (n = 53) using quantitative reverse transcription polymerase chain reaction, gene sequencing, and immunohistochemical analysis. Results: CD44st and MMP2 expression were closely associated with the histopathological classification, lymph node metastasis, and TNM stage of the tumors, and the difference was statistically significant (p < 0.05). The median overall survival (OS) for the high CD44st expression group was 30.52 months (95% confidence interval (CI) 24.02-36.15); for the low expression group it was 43.23 months (95% CI 31.81-52.02) (p = 0.020). The median OS for the high MMP-2 expression group was 30.53 months (95% CI 26.69-33.31); for the low expression group it was 40.06 months (95% CI 33.55-46.45) (p = 0.022). Conclusion: The rates of CD44st and MMP2 expression were higher in squamous cell carcinomas than in adenocarcinomas, were closely associated with lymph node metastasis and TNM stage, and affected patients' prognoses.

show abstract

Section: Discussionmentioning

confidence: 97%

Expression of Novel CD44st and MMP2 in NSCLC Tissues and Their Clinical Significance

Zhang

Hai

et al. 2017

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…CD44 rs187115 was associated with an increased risk of tumor-related death and lower drug sensitivity in sarcoma [13]. CD44 rs187115 is also correlated with bone metastasis and tumor stage in non small cell lung cancer (NSCLC) patients [14]. Although CD44 polymorphism is very important for cancers, few reports showed the roles of CD44 polymorphism in colon and gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses

2016

Oncotarget

View full text Add to dashboard Cite

CD44 is a well-recognized stem cell biomarker expressed in colon and gastric cancer. In order to identify whether CD44 mRNA could be used as a prognostic marker in colon and gastric cancer, bioinformatic analyses were used in this study. cBioPortal analysis and COSMIC analysis were used to explore the CD44 mutation. CD44 mRNA levels were evaluated by using SAGE Genie tools and Oncomine analysis. Kaplan-Meier Plotter was performed to identify the prognostic roles of CD44 mRNA in these two cancers. In this study, first, we found that low alteration frequency of CD44 mRNA in colon and gastric cancer. Second, the high CD44 mRNA level was found in colon and gastric cancer, and it correlated with a benign survival rate in gastric cancer. Third, CD4 and CD74 may be used as markers to predict the prognosis of colon and gastric cancer. However, the deep mechanism(s) of these results remains unclear, further studies have to be performed in the future.

show abstract

“…Thus, we included only five studies with 1716 cancer cases and 2065 controls for rs187115 meta-analysis [36, 38, 44-46]. The MAF for rs187115 ranged from 13 to 22%.…”

Section: Resultsmentioning

confidence: 99%

Quantitative assessment of CD44 genetic variants and cancer susceptibility in Asians: a meta-analysis

et al. 2016

View full text Add to dashboard Cite

CD44 is a well-established cancer stem cell marker playing a crucial role in tumor metastasis, recurrence and chemo-resistance. Genetic variants of CD44 have been shown to be associated with susceptibility to various cancers; however, the results are confounding. Hence, we performed a meta-analysis to clarify these associations more accurately. Overall, rs13347 (T vs. C: OR=1.30, p=<0.004, pcorr=0.032; CT vs. CC: OR=1.29, p=0.015, pcorr=0.047; TT vs. CC: OR=1.77, p=<0.000, pcorr=0.018; CT+TT vs. CC: OR=1.34, p=<0.009, pcorr=0.041) and rs187115 (GG vs. AA: OR=2.34, p=<0.000, pcorr=0.025; AG vs. AA: OR=1.59, p=<0.000, pcorr=0.038; G vs. A allele OR=1.56, p=0.000, pcorr=0.05; AG+GG vs. AA: OR=1.63, p=<0.000, pcorr=0.013) polymorphisms were found to significantly increase the cancer risk in Asians. On the other hand, rs11821102 was found to confer low risk (A vs. G: OR=0.87, p=<0.027, pcorr=0.04; AG vs. GG: OR=0.85, p=<0.017, pcorr=0.01; AG+AA vs. GG: OR=0.86, p=<0.020, pcorr=0.02). Based on our analysis, we suggest significant role of CD44 variants (rs13347, rs187115 and rs11821102) in modulating individual's cancer susceptibility in Asians. Therefore, these variants may be used as predictive genetic biomarkers for cancer predisposition in Asian populations. However, more comprehensive studies involving other cancers and/or populations, haplotypes, gene-gene and gene-environment interactions are necessary to delineate the role of these variants in conferring cancer risk.

show abstract

Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis

Cited by 27 publications

References 49 publications

Expression of Novel CD44st and MMP2 in NSCLC Tissues and Their Clinical Significance

Expression of Novel CD44st and MMP2 in NSCLC Tissues and Their Clinical Significance

Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses

Quantitative assessment of CD44 genetic variants and cancer susceptibility in Asians: a meta-analysis

Contact Info

Product

Resources

About